Clinicopathological features of rare BRAF mutations in korean thyroid cancer patients

Journal of Korean Medical Science

Volumn 29, Issue 8, 2014, Pages 1054-1060

  Cho, Uiju ^a   Oh, Woo Jin ^a   Bae, Ja Seong ^a   Lee, Sohee ^a   Lee, Young Sub ^a   Park, Gyeong Sin ^a   Lee, Youn Soo ^a   Jung, Chan Kwon ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Biomarkers; BRAF; Mutation; Pathology; Thyroid neoplasms

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN; GENETIC MARKER; TUMOR MARKER;

FEMALE; GENETIC MARKER; GENETIC PREDISPOSITION; GENETICS; HUMAN; INCIDENCE; MALE; MIDDLE AGED; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PREVALENCE; RARE DISEASES; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SOUTH KOREA; THYROID NEOPLASMS;

BASE SEQUENCE; FEMALE; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PREVALENCE; PROTO-ONCOGENE PROTEINS B-RAF; RARE DISEASES; REPUBLIC OF KOREA; RISK FACTORS; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84934917373     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2014.29.8.1054     Document Type: Article

References (30)

1. Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol 2011; 7: 569-80.
2. Jung CK, Im SY, Kang YJ, Lee H, Jung ES, Kang CS, Bae JS, Choi YJ. Mutational patterns and novel mutations of the BRAF gene in a large cohort of Korean patients with papillary thyroid carcinoma. Thyroid 2012; 22: 791-7.
3. Trovisco V, Vieira de Castro I, Soares P, Máximo V, Silva P, Magalhães J, Abrosimov A, Guiu XM, Sobrinho-Simões M. BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol 2004; 202: 247-51.
4. Lupi C, Giannini R, Ugolini C, Proietti A, Berti P, Minuto M, Materazzi G, Elisei R, Santoro M, Miccoli P, et al. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab 2007; 92: 4085-90.
5. Lima J, Trovisco V, Soares P, Máximo V, Magalhães J, Salvatore G, Santoro M, Bogdanova T, Tronko M, Abrosimov A, et al. BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas. J Clin Endocrinol Metab 2004; 89: 4267-71.
6. Den Dunnen JT, Antonarakis SE. Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mutat 2000; 15: 7-12.
7. Trovisco V, Soares P, Preto A, de Castro IV, Lima J, Castro P, Máximo V, Botelho T, Moreira S, Meireles AM, et al. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Arch 2005; 446: 589-95.
8. Kim WY, Ko YS, Hwang TS, Han HS, Lim SD, Kim WS, Oh SY. A case of multifocal papillary thyroid carcinoma consisting of one encapsulated follicular variant with BRAF K601E mutation and three conventional types with BRAF V600E mutation. Korean J Pathol 2013; 47: 293-8.
9. Castro P, Rebocho AP, Soares RJ, Magalhães J, Roque L, Trovisco V, Vieira de Castro I, Cardoso-de-Oliveira M, Fonseca E, Soares P, et al. PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab 2006; 91: 213-20.
10. Pennelli G, Vianello F, Barollo S, Pezzani R, Merante Boschin I, Pelizzo MR, Mantero F, Rugge M, Mian C. BRAF(K601E) mutation in a patient with a follicular thyroid carcinoma. Thyroid 2011; 21: 1393-6.
11. Schulten HJ, Salama S, Al-Mansouri Z, Alotibi R, Al-Ghamdi K, Al-Hamour OA, Sayadi H, Al-Aradati H, Al-Johari A, Huwait E, et al. BRAF mutations in thyroid tumors from an ethnically diverse group. Hered Cancer Clin Pract 2012; 10: 10.
12. Goutas N, Vlachodimitropoulos D, Bouka M, Lazaris AC, Nasioulas G, Gazouli M. BRAF and K-RAS mutation in a Greek papillary and medullary thyroid carcinoma cohort. Anticancer Res 2008; 28: 305-8.
13. Cerrato A, De Falco V, Santoro M. Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets. J Mol Endocrinol 2009; 43: 143-55.
14. Oler G, Ebina KN, Michaluart P Jr, Kimura ET, Cerutti J. Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis reveals a new mutation in metastasis. Clin Endocrinol (Oxf) 2005; 62: 509-11.
15. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004; 116: 855-67.
16. Hou P, Liu D, Xing M. Functional characterization of the T1799-1801del and A1799-1816ins BRAF mutations in papillary thyroid cancer. Cell Cycle 2007; 6: 377-9.
17. Di Cristofaro J, Silvy M, Lanteaume A, Marcy M, Carayon P, De Micco C. Expression of tpo mRNA in thyroid tumors: quantitative PCR analysis and correlation with alterations of ret, Braf , ras and pax8 genes. Endocr Relat Cancer 2006; 13: 485-95.
18. Matsuse M, Mitsutake N, Tanimura S, Ogi T, Nishihara E, Hirokawa M, Fuziwara CS, Saenko VA, Suzuki K, Miyauchi A, et al. Functional characterization of the novel BRAF complex mutation, BRAF (V600delinsYM), identified in papillary thyroid carcinoma. Int J Cancer 2013; 132: 738-43.
19. De Falco V, Giannini R, Tamburrino A, Ugolini C, Lupi C, Puxeddu E, Santoro M, Basolo F. Functional characterization of the novel T599I-VKSRdel BRAF mutation in a follicular variant papillary thyroid carcinoma. J Clin Endocrinol Metab 2008; 93: 4398-402.
20. Moretti S, Macchiarulo A, De Falco V, Avenia N, Barbi F, Carta C, Cavaliere A, Melillo RM, Passeri L, Santeusanio F, et al. Biochemical and molecular characterization of the novel BRAF (V599Ins) mutation detected in a classic papillary thyroid carcinoma. Oncogene 2006; 25: 4235-40.
21. Kim TY, Kim WB, Rhee YS, Song JY, Kim JM, Gong G, Lee S, Kim SY, Kim SC, Hong SJ, et al. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2006; 65: 364-8.
22. Jung CK, Little MP, Lubin JH, Brenner AV, Wells SA Jr, Sigurdson AJ, Nikiforov YE. The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J Clin Endocrinol Metab 2014; 99: E276-85.
23. Trovisco V, Soares P, Soares R, Magalhães J, Sá-Couto P, Sobrinho-Simões M. A new BRAF gene mutation detected in a case of a solid variant of papillary thyroid carcinoma. Hum Pathol 2005; 36: 694-7.
24. Lee SR, Jung CK, Kim TE, Bae JS, Jung SL, Choi YJ, Kang CS. Molecular genotyping of follicular variant of papillary thyroid carcinoma correlates with diagnostic category of fine-needle aspiration cytology: values of RAS mutation testing. Thyroid 2013; 23: 1416-22.
25. Jang MA, Lee ST, Oh YL, Kim SW, Chung JH, Ki CS, Kim JW. Identification of a rare 3 bp BRAF gene deletion in a thyroid nodule by mutant enrichment with 3'-modified oligonucleotides polymerase chain reaction. Ann Lab Med 2012; 32: 238-41.
26. Santarpia L, Sherman SI, Marabotti A, Clayman GL, El-Naggar AK. Detection and molecular characterization of a novel BRAF activated domain mutation in follicular variant of papillary thyroid carcinoma. Hum Pathol 2009; 40: 827-33.
27. Chiosea S, Nikiforova M, Zuo H, Ogilvie J, Gandhi M, Seethala RR, Ohori NP, Nikiforov Y. A novel complex BRAF mutation detected in a solid variant of papillary thyroid carcinoma. Endocr Pathol 2009; 20: 122-6.
28. Barzon L, Masi G, Boschin IM, Lavezzo E, Pacenti M, Casal Ide E, Toniato A, Toppo S, Palù G, Pelizzo MR. Characterization of a novel complex BRAF mutation in a follicular variant papillary thyroid carcinoma. Eur J Endocrinol 2008; 159: 77-80.
29. Trovisco V, Couto JP, Cameselle-Teijeiro J, de Castro IV, Fonseca E, Soares P, Sobrinho-Simões M. Acquisition of BRAF gene mutations is not a requirement for nodal metastasis of papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2008; 69: 683-5.
30. Gauchotte G, Philippe C, Lacomme S, Léotard B, Wissler MP, Allou L, Toussaint B, Klein M, Vignaud JM, Bressenot A. BRAF, p53 and SOX2 in anaplastic thyroid carcinoma: evidence for multistep carcinogenesis. Pathology 2011; 43: 447-52.